Category | Distribution and% |
---|---|
Age (median, range) | 61 (34–77) |
2009 FIGO stage | |
IIIA | 7 (35%) |
IIIC | 5 (25%) |
IIIC1 | 2 (10%) |
IIIC2 | 3 (15%) |
IVB | 7 (35%) |
No classification available * | 1 (5%) |
Histology | |
Endometrioid (pure) | 13 (65%) |
Papillary serous (pure) | 4 (20%) |
Papillary serous (mixed) | 3 (15%) |
Grade | |
1 | 3 (15%) |
2 | 7 (35%) |
3 | 10 (50%) |
Nodal status | |
pN0 | 11 (55%) |
pN+ | 6 (30%) |
pNx | 3 (15%) |
Peritoneal cytology | |
Positive or suspicious for malignant cells | 15 (75%) |
Negative | 4 (20%) |
Not done | 1 (5%) |
SURGERY | |
Surgical approach | |
Laparotomy | 15 (75%) |
Laparoscopy | 5 (25%) |
Lymph node dissection performed | 17 (85%) |
Pelvic only | 8 (40%) |
Pelvic + PA | 9 (45%) |
Total number of dissected LN (median, range) | 18 (3–46) |
CHEMOTHERAPY | |
Number of cycles (received/planned) | |
0/6 cycles | 2 (10%) |
3/3 cycles | 2 (10%) |
4/6 cycles | 1 (5%) |
5/6 cycles | 1 (5%) |
6/6 cycles | 14 (70%) |
Drug combination (n = 18) | |
TP | 14 (78%) |
TAP | 4 (22%) |
RADIOTHERAPY | |
WAI total dose (median, range) | |
Total dose (Gy) | 27.5 (20–30) |
Daily dose (Gy) | 1.25 (1.0 - 1.25 |
Additional volume (boost) | |
Pelvic only | 7 (35%) |
Pelvic + PA | 2 (10%) |
Cumulative total dose(median, range) | |
Pelvis (Gy) | 46.7 (44.8 - 48) |
PA (Gy) | 46.7 (44.8 - 55.7) |
Vaginal cuff brachytherapy | 17 (85%) |
Dose (median, range) | |
Total dose (Gy) | 18 (13–21) |
Number of fractions | 3 (3–5) |
TIMING (median, range) | |
Between surgery and chemo start (days) | 24 (9–48) |
Between end of chemo and RT start (days) | 48 (21–104) |
Between surgery and completion of all treatments (months) | 5.7 (1.5 - 7.6) |
Duration of RT (elapsed days) | 35 (11–55) |